<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066832</url>
  </required_header>
  <id_info>
    <org_study_id>Eur-001</org_study_id>
    <nct_id>NCT01066832</nct_id>
  </id_info>
  <brief_title>The Valentines Trial</brief_title>
  <official_title>The Valentines Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurocor GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurocor GmbH</source>
  <brief_summary>
    <textblock>
      The primary objective of this multi-center, international, short term registry is to assess
      clinical success and efficacy of the paclitaxel eluting balloon treatment for in-stent
      restenosis at 6-9 months follow up. Clinical success defined as freedom from major adverse
      cardiac events (MACE: death, myocardial infarction [MI], target lesion revascularization
      [TLR]) and target vessel revascularization [TVR]) and stent thrombosis, both early and late
      occurrences will be assessed.

      In addition, a cohort of the registry will undergo angiographic follow up at 6-9 months to
      assess in-stent and in-segment late loss and binary restenosis subsequent to paclitaxel
      eluting balloon treatment for in-stent restenosis.

      A prioi analysis will be comparison of the safety and efficacy of patients presenting with
      drug-eluting stent in-stent restenosis to bare metal stent in-stent restenosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical success at 6-9 month defined as freedom from MACE, death, MI,TLR and stent thrombosis</measure>
    <time_frame>6-9 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment late loss and binary restenosis</measure>
    <time_frame>6-9 month</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">276</enrollment>
  <condition>Instent Restenosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel-coated balloon (3 Âµg/mm2)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients, male or female, &gt; 18 years of age;

          -  Patients who present with in-stent restenosis of a previously placed stent documented
             by coronary angiogram for which re-PCI is planned;

          -  The patient has stable or unstable angina, and/or clinical evidence of ischemia (ECG,
             exercise test, etc.);

          -  The target lesion is in a native vessel;

          -  Up to two lesions per patient;

          -  Target lesion(s) stenosis is &gt; 50%.

        Exclusion Criteria:

          -  The patient has had an acute myocardial infarction within the last 48 hours;

          -  The patient has a co-morbid illness (i.e. any illness likely to limit his/her life
             expectancy to &lt;12 months);

          -  Lesion(s) requiring additional stenting either bare metal or drug eluting (non,
             bail-out indications);

          -  The patient has had previous therapeutic radiation to the target vessel;

          -  The patient is unable the take dual antiplatelet therapy for at least 6 months;

          -  Patients with three or more lesions with in-stent restenosis requiring angioplasty.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter Stella, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht, Utrecht, Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sigmund Silber, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Munich at the Isar, Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Sangiorgi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Modena, Modena, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center Munich at the Isar</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.valentines-trial.com</url>
    <description>Homepage of the trial</description>
  </link>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <last_update_submitted>June 16, 2011</last_update_submitted>
  <last_update_submitted_qc>June 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Rembert Pogge von Strandmann</name_title>
    <organization>Eurocor GmbH</organization>
  </responsible_party>
  <keyword>Drug-eluting balloon</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>DIOR</keyword>
  <keyword>short term registry</keyword>
  <keyword>Valentines Trial</keyword>
  <keyword>Drug-eluting balloon treatment of in-stent restenosis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

